dead money because the partner not really interested in marketing as POZN wanted. Which means lower royalties and in the case POZN partner already has enough enough.... so why would they go for aggressive marketing.. if it sells well and good ... if it doesn't who really cares..
So all the excitement about POZN hitting $20 is premature
HONO2003: how can you compare,SCMP,withPOZN?.didSCMP,paid you ,1,75 div.?.I BOUGHT POZN, last week again, and plan to add,a few hundred shares at a time;to build a good portfolio. MY aim is ten thousand.GLTA
cold, I never mentioned SCMP and never compared SCMP with POZN, please read the thread. The thread concerning SCMP was started by brainytrader and I think its a real nonsense to establish any relationship of POZNs product and SCMPs fate.
Your dead money scenario is very unlikely. Sanofi has an established sales force and very good access to the docs who are the top prescriber for such products. Sanofi is fully committed to PA - the licence deal is just 5 months old and nothing has changed. Here some statements from Sanofi when Sanofi signed the deal:
"Sanofi has a strong heritage and expertise in the cardiovascular space, with Lovenox, Plavix, and most recently Multaq, and the PA products are an important addition to our already strong CV portfolio," said Anne Whitaker, President, North America Pharmaceuticals at Sanofi US. "The PA products have the potential to be an effective solution for the millions of patients at risk for gastric ulcers from chronic aspirin use in the prevention of secondary cardiovascular disease. We look forward to bringing this therapy to patients and healthcare providers."
Sanofi US will have responsibility for all sales, marketing, ongoing manufacturing and future development for the licensed PA products in the U.S. POZEN will retain responsibility for obtaining approval of the New Drug Application (NDA), after which time POZEN will transfer the NDA to Sanofi US. The NDA was submitted in March 2013 and accepted for filing in May 2013 by the U.S. Food and Drug Administration (FDA).
I wouldn't bet on that Hofno2003 ; you are dead wrong, Takeda too had everything which you claim for Sanofi. Good luck on that.........what applied to Sanofi applied to Takeda too...
so POZN is another SCMP
U.S. drugmaker Sucampo Pharmaceuticals is seeking talks with marketing partner Takeda Pharmaceutical Co Ltd to mend their relationship, after losing a two-year legal battle to sever ties with the Japanese company.
The International Court of Arbitration ruled against Sucampo on Friday in a dispute resulting from the biotechnology company's dissatisfaction with Takeda's marketing of its constipation drug, Amitiza.
The company, which had sought damages and wanted to dissolve its tie-up with Takeda, depends on Amitiza for most of its revenue, derived from royalties paid by Takeda.
Sucampo, which signed the deal with Takeda in 2004, began arbitration in 2010, alleging that its Japanese partner's meek marketing of Amitiza had failed to drive satisfactory sales.